D. Cunningham, I. Chau, D. Stocken
Nov 20, 2009
Citations
15
Influential Citations
696
Citations
Quality indicators
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Abstract
PURPOSE
Both gemcitabine (GEM) and fluoropyrimidines are valuable treatment for advanced pancreatic cancer. This open-label study was designed to compare the overall survival (OS) of patients randomly assigned to GEM alone or GEM plus capecitabine (GEM-CAP).
PATIENTS AND METHODS
Patients with previously untreated histologically or cytologically proven locally advanced or metastatic carcinoma of the pancreas with a performance status